全文获取类型
| 收费全文 | 290451篇 |
| 免费 | 18314篇 |
| 国内免费 | 6246篇 |
专业分类
| 耳鼻咽喉 | 3527篇 |
| 儿科学 | 7762篇 |
| 妇产科学 | 5358篇 |
| 基础医学 | 23055篇 |
| 口腔科学 | 6885篇 |
| 临床医学 | 35217篇 |
| 内科学 | 35297篇 |
| 皮肤病学 | 3714篇 |
| 神经病学 | 16697篇 |
| 特种医学 | 6494篇 |
| 外国民族医学 | 22篇 |
| 外科学 | 30212篇 |
| 综合类 | 42685篇 |
| 现状与发展 | 12篇 |
| 一般理论 | 24篇 |
| 预防医学 | 29599篇 |
| 眼科学 | 4485篇 |
| 药学 | 24955篇 |
| 393篇 | |
| 中国医学 | 27260篇 |
| 肿瘤学 | 11358篇 |
出版年
| 2024年 | 3441篇 |
| 2023年 | 5647篇 |
| 2022年 | 8833篇 |
| 2021年 | 11778篇 |
| 2020年 | 11209篇 |
| 2019年 | 15797篇 |
| 2018年 | 13520篇 |
| 2017年 | 10936篇 |
| 2016年 | 8901篇 |
| 2015年 | 8255篇 |
| 2014年 | 16590篇 |
| 2013年 | 18436篇 |
| 2012年 | 15091篇 |
| 2011年 | 16168篇 |
| 2010年 | 13017篇 |
| 2009年 | 11854篇 |
| 2008年 | 11692篇 |
| 2007年 | 12146篇 |
| 2006年 | 10584篇 |
| 2005年 | 9160篇 |
| 2004年 | 7429篇 |
| 2003年 | 6560篇 |
| 2002年 | 5142篇 |
| 2001年 | 4677篇 |
| 2000年 | 3818篇 |
| 1999年 | 3302篇 |
| 1998年 | 2689篇 |
| 1997年 | 2553篇 |
| 1996年 | 2223篇 |
| 1995年 | 2108篇 |
| 1994年 | 2025篇 |
| 1993年 | 1583篇 |
| 1992年 | 1623篇 |
| 1991年 | 1438篇 |
| 1990年 | 1230篇 |
| 1989年 | 1089篇 |
| 1988年 | 1081篇 |
| 1985年 | 2995篇 |
| 1984年 | 3797篇 |
| 1983年 | 2693篇 |
| 1982年 | 3115篇 |
| 1981年 | 2827篇 |
| 1980年 | 2521篇 |
| 1979年 | 2323篇 |
| 1978年 | 2000篇 |
| 1977年 | 1541篇 |
| 1976年 | 1756篇 |
| 1975年 | 1285篇 |
| 1974年 | 1124篇 |
| 1973年 | 1045篇 |
排序方式： 共有10000条查询结果，搜索用时 0 毫秒
71.
72.
73.
74.
J.C. Rodríguez-Sanjuán N. Ruiz E. Miñambres E. Toledo M. González-Noriega R. Fernández-Santiago F. Castillo 《Transplantation proceedings》2019,51(1):12-19
Background
Liver transplantation from donors after either controlled or uncontrolled cardiac death (DCD) is associated with considerable rates of primary nonfunction (PNF) and ischemic cholangiopathy (IC). Normothermic regional perfusion (NRP) could significantly reduce such rates.Methods
Retrospective study to analyze short-term (mortality, PNF, vascular complications) and long-term (IC, survival) complications in 11 liver transplants from controlled DCDs using NRP with extracorporeal membrane oxygenation (ECMO) (group 1). They were compared with 51 patients transplanted with grafts from donors after brain death (DBD) (group 2). Mean recipient age, sex, and Model for End-stage Liver Disease (MELD) score were not significantly different.Results
In group 1, mean functional warm ischemia time was 15.8 (range, 7–40) minutes and 94.1 (range, 20–150) minutes on NRP. The ischemic damage was minimal, as shown by the slight alanine aminotransferase (ALT) and aspartate aminotransferase (AST) rises in the donor serum after 1 hour on NRP and similar rises 24 hours after transplantation in both groups. No patient had IC or acute renal failure. No significant difference was found between the groups for vascular or biliary complications. One group 1 patient had PNF (9.1%), resulting in death. Overall retransplantation and in-hospital death rates were 8.1% and 4.8%, respectively, with no significant difference between groups. Estimated mean survival was 24.6 (95% confidence interval [CI], 20.2–29.1) months in group 1 and 32.3 (95% CI, 30.4–34.2) months in group 2 (not a statistically significant difference).Conclusion
In our experience, liver transplants from controlled DCDs using NRP with ECMO is associated with a low risk of PNF and IC, with short- and long-term results comparable to those in DBD transplants. 相似文献75.
76.
Hanna Lee Mary K. Tan Andrew T. Yan Paul Angaran Paul Dorian Claudia Bucci Jean C. Gregoire Alan D. Bell Martin S. Green Peter L. Gross Allan Skanes Charles R. Kerr L. Brent Mitchell Jafna L. Cox Vidal Essebag Brett Heilbron Krishnan Ramanathan Carl Fournier Shaun G. Goodman 《The Canadian journal of cardiology》2019,35(2):160-168
Background
Physicians treating nonvalvular atrial fibrillation (AF) assess stroke and bleeding risks when deciding on anticoagulation. The agreement between empirical and physician-estimated risks is unclear. Furthermore, the association between patient and physician sex and anticoagulation decision-making is uncertain.Methods
We pooled data from 2 national primary care physician chart audit databases of patients with AF (Facilitating Review and Education to Optimize Stroke Prevention in Atrial Fibrillation and Coordinated National Network to Engage Physicians in the Care and Treatment of Patients with Atrial Fibrillation Chart Audit) with a combined 1035 physicians (133 female, 902 male) and 10,927 patients (4567 female and 6360 male).Results
Male physicians underestimated stroke risk in female patients and overestimated risk in male patients. Female physicians estimated stroke risk well in female patients but underestimated the risk in male patients. Risk of bleeding was underestimated in all. Despite differences in risk assessment by physician and patient sex, > 90% of patients received anticoagulation across all subgroups. There was modest agreement between physician estimated and calculated (ie, CHADS2 score) stroke risk: Kappa scores were 0.41 (0.35-0.47) for female physicians and 0.34 (0.32-0.36) for male physicians.Conclusions
Our study is the first to examine the association between patient and physician sex influences and stroke and bleeding risk estimation in AF. Although there were differences in agreement between physician estimated stroke risk and calculated CHADS2 scores, these differences were small and unlikely to affect clinical practice; further, despite any perceived differences in the accuracy of risk assessment by sex, most patients received anticoagulation. 相似文献77.
78.
V. Jenkins I. Solis-Trapala H. Payne M. Mason L. Fallowfield S. May L. Matthews S. Catt 《Clinical oncology (Royal College of Radiologists (Great Britain))》2019,31(2):99-107
Aims
Delaying progression, ameliorating symptoms and maintaining quality of life (QoL) are primary aims of treatment for metastatic castrate-resistant prostate cancer (mCRPC). Real-world rather than clinical trial data about symptoms and side-effects are sparse. In EXTREQOL, patients' QoL, pain and information needs were recorded during treatment.Material and methods
Men with mCRPC from 20 UK cancer centres starting various systemic mCRPC treatments completed QoL, pain and information needs questionnaires at baseline, 3 and 6 months.Results
In total, 132 patients were recruited. Overall QoL declined significantly by 6 months (Functional Assessment of Cancer Therapy-Prostate [FACT-P] mean = –3.89, 95% confidence interval –6.7 to –1.05, P = 0.007; Trial Outcome Index [TOI] analysis mean = –3.10, 95% confidence interval –5.34 to –0.83, P = 0.007). Those who came off novel therapy and remained on luteinising hormone-releasing hormone agonist therapy alone had worse scores than patients receiving concomitant chemotherapy (Prostate Concerns Subscale mean difference = –4.45, 95% confidence interval –7.06 to –1.83, P = 0.001; TOI mean difference = –5.62, 95% confidence interval –10.97 to –0.26, P = 0.040). At 3 and 6 months, men who reported pain at baseline improved (43%, 40%), but for others pain levels remained the same (45%, 42%) or worsened (13%, 18%). Information regarding supportive care was lacking throughout the period of time on the study.Conclusion
Most mCRPC treated patients experience reduced QoL and inadequate pain control. More help with pain management and better information provision regarding supportive care is warranted. 相似文献79.
80.